GW Pharmaceuticals plc plans to sell $225 million of American depositary shares on the Nasdaq Global Market in an underwritten U.S. public offering.
The ADS represent ordinary shares of the company.
The company expects to grant the underwriters a 30-day option to buy up to an additional $33.75 million ADS at the offering price.
Goldman Sachs & Co. LLC, Morgan Stanley, Bank of America Merrill Lynch and Cowen are acting as joint book-running managers for the offering.
